Catalyst Pharmaceuticals Faces Pivotal Earnings Release
Published on 11/02/2025 at 07:08 | Redaktion boerse-global.de
Investors in Catalyst Pharmaceuticals are bracing for a significant market-moving event this week as the biopharma company prepares to release its third-quarter 2025 financial results. The upcoming earnings announcement, scheduled for Wednesday, is anticipated to set the near-term trajectory for the company’s stock performance.
The financial community will be closely examining Catalyst’s earnings report, due after market close on November 5. Current forecasts present a contrasting picture of the company’s performance. Revenue is projected to increase by 6 percent to $136.43 million, while earnings per share are expected to decline by 10.5 percent to $0.51. According to consensus estimates from three market analysts, the average EPS prediction stands at just $0.48, with individual forecasts ranging Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
